• Publications
  • Influence
67 TELAPREVIR WITH ADJUSTED DOSE OF RIBAVIRIN IN NAIVE CHC-G1: EFFICACY AND TREATMENT IN CHC IN HEMODIALYSIS POPULATION. TARGET C (RCT)
PWE-126 Table AVR 1 week VRVR 2 weeks RVR 4 weeks EVR 12 weeks MTVR 18 weeks ETVR 24weeks SVR 48 weeks SVR 60 weeks SVR 72 weeks Group A n=18 SVR 24 weeks VL 820k G1a 8 G1b 7 Il28b CC 5 TT 5 CT 8Expand
PWE-127 Restless Leg Syndrome, (RLS) is Associated with Hepatic Encephalopathy (He) in Decompensated Cirrhosis. A Clinical Pilot Study
Introduction RLS affects 10% of the general population, affecting the quality of life (QOL). Exact aetiology is still unknown. Iron deficiency, small intestinal bacterial overgrowth (SIBO) andExpand
PWE-129 Pegylated Interferon Alfa, Nitazoxanide, Telaprevir, Ribavirin, in Genotype 1 Undergoing Prior Experienced Chc-A Randomized Placebo Control Clinical Pilot Trial (Intrigue-C)
TLDR
This quadruple 24 weeks regimen has excelled the RVR, EVR, ETVT over SOC with DAAs over 11%, with SVR 67%. Expand
Pattern of compliance to anti- hypertensive medications in hypertensive patients in a tertiary care hospital in Bangladesh
TLDR
Most of the populations are compliant but yet significant number of populations are non-compliant, and collective participation of physician, patient and health care delivery system can improve the situation more. Expand
PWE-126 Telaprevir With Adjusted dose of Ribavirin in Naive Chc-G1: Efficacy and Treatment in Chc In Hemodialysis Population. Target C (Rct)
TLDR
This study demonstrates higher SVR comparing traditional SOC on hemodialysis CHC-G1 patients, and Telaprevir is not cleared renally and hence is safe in dialysis population. Expand
PWE-130 Effect Of N Acetylcysteine (NAC) in Hypoxia Induced Liver Injury (HILI)–A Randomized Placebo Control Clinical Trial
Introduction HILI is common with a prevalence of 10% in US. Transient shift of intra hepatic hemodynamic compromise leads to tissue hypoxia and induces hypoxia induced protein (HIP), heat shockExpand
PWE-128 Romiplostim’S Effect to Optimize SVR With Telapravir, Ribavirin, and Peg Interferon-Alfa 2A In Thrombocytopenic Cirrhotics with Chronic Hepatitis C. A Placebo Controlled Prospective Clinical
Introduction Treating HCV cirrhotic patients with thrombocytopenia is challenging, often requiring dose reduction/discontinuation to avoid complications. Significant dose reduction affects responseExpand
OC-053 Curcumin, Anti-Oxidant, and Pioglitazone Therapy with Inclusion of Vitamin E in Non Alcoholic Fatty Liver Disease-A Randomized open Label Placebo Controlled Clinical Prospective Trial (Captive)
Introduction NAFLD is a global clinical challenge which progresses to cirrhosis and liver cancer. Defective transport of free fatty acids and mitochondrial dysfunction lead to explosion of a seriesExpand
906 ROMIPLOSTIM'S EFFECT TO OPTIMIZE SVR WITH TELAPRAVIR, RIBAVIRIN, AND PEG INTERFERON-alfa 2a IN THROMBOCYTOPENIC CIRRHOTICS WITH CHRONIC HEPATITIS C. RESTRAINT C- PLACEBO RCT
TLDR
This work presents results from the phase III OPTIMIZE study on drug-naive HCV-infected patients at Kings College London, London, UK, which compared adherence with TelapreVIR BID vs. q8h DOSing in treatment-NAIVE HCv-infECTed patients. Expand
...
1
2
...